Benefits
Digestive Comfort
The company markets Biombalance for day-to-day digestive comfort, but there is no published human trial to support that. The satisfaction figures the manufacturer quotes have never been peer reviewed or independently checked, so there is no way to know how many people took part, who they were, or whether anyone received a placebo.
Balanced Gut Microbiota
Grape seed proanthocyanidins are poorly absorbed, so they reach the colon where gut bacteria ferment them. In one mouse study, animals given Biombalance by feeding tube for 10 days before a chemical that damages the colon showed less disruption of their gut bacteria than untreated animals. That study was co-written by employees of the company that sells Biombalance, and mice are not people.
Gut Inflammation Markers (Mice Only)
In one mouse study, Biombalance given before a chemical that induces colitis lowered inflammation markers in the gut lining and helped preserve the gut barrier. That chemical model is a laboratory model of inflammatory bowel disease, a diagnosed medical condition, so it says nothing about everyday digestive comfort in a healthy person. Nothing similar has been tested in humans.
Antioxidant Support
Like other grape seed OPC extracts, Biombalance neutralizes free radicals in test-tube assays. That is a laboratory measurement. No study has shown that taking Biombalance changes oxidative stress in a person's digestive tract.
Gut-Brain Axis Signaling (Emerging)
In cultured human intestinal cells and in mice, Biombalance increased expression of gut signaling molecules including GLP-1 and neuropeptide Y. This is early laboratory and animal work from the manufacturer's own research team. Nothing about appetite, mood or digestion in people follows from it, and there are no human trials at all, large or small.
Mechanism of action
B-Type Proanthocyanidin Antioxidant Activity
Biombalance is concentrated in oligomeric procyanidins, which donate electrons to neutralize reactive oxygen species in laboratory assays. Whether that regulates oxidative stress in a human gut lining has not been tested.
Microbiota Modulation
Poorly absorbed in the upper gut, grape seed OPCs reach the colon largely intact, where resident bacteria metabolize them. For Biombalance specifically, shifts in gut bacteria have been measured only in mice, not in people.
Anti-Inflammatory Signaling
In mice with chemically induced colitis, Biombalance lowered inflammatory markers in the colon (the study measured IL-6, IL-17 and TNF-alpha among others) and helped maintain the gut barrier. That is animal work in a disease model and it has not been repeated in people.
Gut-Brain Axis and GLP-1 (Preclinical)
In cell culture and in mice, Biombalance increased intestinal expression of GLP-1 and its receptor and of neuropeptide Y. These pathways link gut signaling to appetite and mood in theory, but no human study has looked at any of it, and both papers were co-written by employees of the manufacturer.
Clinical trials
Animal study in mice, published in Antioxidants (2025). Biombalance was given by feeding tube for 10 days before colitis was induced with 2.75 percent DSS in the drinking water. Three of the authors are employees of Groupe Berkem, the company that makes Biombalance.
Mice with induced colitis.
Compared with untreated colitis animals, mice given Biombalance had less colon inflammation, less disruption of their gut bacteria, and a better preserved gut barrier. DSS colitis is a laboratory model of inflammatory bowel disease, so this is animal research about a disease, not evidence of a digestive comfort benefit for consumers.
Laboratory study published in Antioxidants (December 2025): tests in cultured Caco-2 human intestinal cells plus mice fed the extract at two doses. Two of the authors are employees of Groupe Berkem, the company that makes Biombalance.
Bacterial cultures, cultured Caco-2 intestinal cells, and live mice. No human participants.
In these cell and mouse tests, Biombalance showed antibacterial, antioxidant and anti-inflammatory activity and increased expression of gut signaling molecules including GLP-1 and neuropeptide Y as the dose rose. None of this was measured in people.
Figures described by Groupe Berkem, the company that sells Biombalance, in its own materials. There is no published paper, no participant count and no way for anyone outside the company to check them.
Not disclosed. The company has not published how many people took part or how they were selected.
The company reports that over 90 percent of participants found their digestive discomfort easier to manage and about 72 percent no longer changed their diet to avoid it. These numbers have never been published or peer reviewed, they come from the seller, and self-reported satisfaction percentages are not the same as a measured effect against a placebo. Treat them as advertising rather than evidence.